High-efficiency purification of divergent AAV serotypes using AAVX affinity chromatography
Molecular Therapy - Methods & Clinical Development · 2023-03 · 28 · 146-159
DOI: 10.1016/j.omtm.2022.12.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy - Methods & Clinical Development, 2023-03. Verfasst von Michael Florea und 8 weiteren Autor:innen. Beteiligte Einrichtung: Grousbeck Gene Therapy Center, Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Boston, MA, USA. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Institutes of Health, Glenn Family Foundation.
Abstract (Originalsprache)
The adeno-associated viral vector (AAV) provides a safe and efficient gene therapy platform with several approved products that have marked therapeutic impact for patients. However, a major bottleneck in the development and commercialization of AAV remains the efficiency, cost, and scalability of AAV production. Chromatographic methods have the potential to allow purification at increased scales and lower cost but often require optimization specific to each serotype. Here, we demonstrate that the POROS CaptureSelect AAVX affinity resin efficiently captures a panel of 15 divergent AAV serotypes, including the commonly used AAV2, AAV8, AAV9, PHP.B, and Anc80. We also find that AAVX resin can be regenerated repeatedly without loss of efficiency or carry-over contamination. While AAV preps purified with AAVX showed a higher fraction of empty capsids than preps purified using iodixanol ultracentrifugation, the potency of the AAVX purified vectors was comparable with that of iodixanol purified vectors both in vitro and in vivo. Finally, optimization of the purification protocol resulted in a process with an overall efficiency of 65%-80% across all scales and AAV serotypes tested. These data establish AAVX affinity chromatography as a versatile and efficient method for purification of a broad range of AAV serotypes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Grousbeck Gene Therapy Center, Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary, Boston, MA, USA.
- Harvard Ph.D. Program in Biological and Biomedical Sciences, Division of Medical Sciences, Harvard University, Boston, MA, USA.
- Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
- Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA.
- Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA.
- Section on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Boston, MA, USA.
Förderung
- NIA NIH HHS
- National Institutes of Health
- Glenn Family Foundation
Zitieren
APA
Florea, M., Nicolaou, F., Pacouret, S., Zinn, E. M., Sanmiguel, J., Andres-Mateos, E., Unzu, C., Wagers, A. J., & Vandenberghe, L. H. (2023). High-efficiency purification of divergent AAV serotypes using AAVX affinity chromatography. Molecular Therapy - Methods & Clinical Development, 28, 146-159. https://doi.org/10.1016/j.omtm.2022.12.009
Vancouver
Florea M, Nicolaou F, Pacouret S, Zinn EM, Sanmiguel J, Andres-Mateos E, et al. High-efficiency purification of divergent AAV serotypes using AAVX affinity chromatography. Molecular Therapy - Methods & Clinical Development. 2023;28:146-159. doi:10.1016/j.omtm.2022.12.009
BibTeX
@article{Florea2023,
author = {Florea, Michael and Nicolaou, Fotini and Pacouret, Simon and Zinn, Eric M and Sanmiguel, Julio and Andres-Mateos, Eva and Unzu, Carmen and Wagers, Amy J and Vandenberghe, Luk H},
title = {High-efficiency purification of divergent AAV serotypes using AAVX affinity chromatography},
journal = {Molecular Therapy - Methods & Clinical Development},
year = {2023},
volume = {28},
pages = {146--159},
doi = {10.1016/j.omtm.2022.12.009}
}
EUVIMED